Company news

Evolus, Inc. Common Stock news in 2024

Evolus, Inc. Common Stock's news releases, calls and decks from 2024, newest first.

View company

Evolus Reports Third Quarter 2024 Results

November 5, 2024

Evolus Announces EU Approval of Estyme® Injectable Hyaluronic Acid Gels Under New Medical Device Regulation

October 30, 2024

Evolus Rewards™ Patient Loyalty Program Surpasses 1 Million Enrolled Consumers

October 28, 2024

Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024

September 5, 2024

Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance

July 30, 2024

Evolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in Australia

July 29, 2024

Evolus Announces Appointment of Albert G. White III to Board of Directors

June 30, 2024

Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse™ Dermal Filler Products

June 23, 2024

Evolus Broadens International Presence with Launch of Nuceiva® (botulinum toxin type A) in Spain

June 11, 2024

Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE Meeting

May 19, 2024

Evolus Reports First Quarter 2024 Results and Provides Business Update

May 6, 2024

Evolus to Report First Quarter Financial Results on May 7, 2024

April 22, 2024

Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®

April 16, 2024

Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock

March 10, 2024

Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance

March 6, 2024

Evolus Announces Results from European Head-to-Head Filler Trial

February 29, 2024

Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024

February 21, 2024

Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Net Revenue, Achieving Record Results and Exceeding Expectations; Issues 2024 Guidance

January 15, 2024

Evolus Announces the Appointment of Nareg Sagherian to Vice President, Head of Global Investor Relations and Corporate Communications

January 3, 2024

Calls in 2024

Decks in 2024